Ravikiran S. Yedidi, Ph.D.
Affiliations: | 2009 | Biochemistry and Molecular Biology | Wayne State University, Detroit, MI, United States |
Area:
Biochemistry, Medical Biophysics, PharmacyGoogle:
"Ravikiran Yedidi"Parents
Sign in to add mentor| Ladislau C. Kovari | grad student | 2009 | Wayne State | |
| (Structure based design of potent inhibitors against multidrug-resistant HIV-1 protease variants.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Amano M, Yedidi RS, Salcedo-Gómez PM, et al. (2022) Fluorine-Modifications Contribute to Potent Antiviral Activity against Highly Drug-Resistant HIV-1 and Favorable Blood-Brain Barrier (BBB) Penetration Property of Novel Central Nervous System (CNS)-targeting HIV-1 Protease Inhibitors . Antimicrobial Agents and Chemotherapy. AAC0171521 |
| Amano M, Salcedo-Gómez PM, Yedidi RS, et al. (2019) Novel Central Nervous System (CNS)-Targeting Protease Inhibitors for Drug-Resistant HIV Infection and HIV-Associated CNS Complications. Antimicrobial Agents and Chemotherapy |
| Aoki M, Hayashi H, Rao KV, et al. (2017) A novel central nervous system-penetrating protease inhibitor overcomes human immunodeficiency virus 1 resistance with unprecedented aM to pM potency. Elife. 6 |
| Amano M, Miguel Salcedo-Gómez P, Yedidi RS, et al. (2017) GRL-09510, a Unique P2-Crown-Tetrahydrofuranylurethane -Containing HIV-1 Protease Inhibitor, Maintains Its Favorable Antiviral Activity against Highly-Drug-Resistant HIV-1 Variants in vitro. Scientific Reports. 7: 12235 |
| Yedidi RS, Wendler P, Enenkel C. (2017) AAA-ATPases in Protein Degradation. Frontiers in Molecular Biosciences. 4: 42 |
| Amano M, Salcedo-Gómez PM, Zhao R, et al. (2016) A Modified P1 Moiety Enhances in vitro Antiviral Activity against Various Multi-Drug-Resistant HIV-1 Variants and in vitro CNS Penetration Properties of a Novel Nonpeptidic Protease Inhibitor, GRL-10413. Antimicrobial Agents and Chemotherapy |
| Aoki M, Hayashi H, Yedidi RS, et al. (2015) The C5-substituted Tetrahydropyrano-tetrahydofuran-derived Protease Inhibitors (PIs) Exert Potent Inhibition of the Replication of HIV-1 Variants Highly Resistant to Various PIs Including Darunavir. Journal of Virology |
| Yedidi RS, Proteasa G, Martin PD, et al. (2014) A multi-drug resistant HIV-1 protease is resistant to the dimerization inhibitory activity of TLF-PafF. Journal of Molecular Graphics & Modelling. 53: 105-11 |
| Yedidi RS, Garimella H, Aoki M, et al. (2014) A conserved hydrogen-bonding network of P2 bis-tetrahydrofuran-containing HIV-1 protease inhibitors (PIs) with a protease active-site amino acid backbone aids in their activity against PI-resistant HIV. Antimicrobial Agents and Chemotherapy. 58: 3679-88 |
| Yedidi RS, Liu Z, Kovari IA, et al. (2014) P1 and P1′ para-fluoro phenyl groups show enhanced binding and favorable predicted pharmacological properties: Structure-based virtual screening of extended lopinavir analogs against multi-drug resistant HIV-1 protease Journal of Molecular Graphics and Modelling. 47: 18-24 |